GleamWall
中文EN

ANIP ANI PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1023024 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY25.9%
TTM net income YoY188.0%
TTM EPS YoY214.4%
Revenue 3-yr CAGR32.3%
Net income 3-yr CAGR105.9%

Margins

Gross margin61.1%
Operating margin16.0%
Net margin11.2%
FCF margin19.7%
EBITDA margin23.9%

Returns

ROE20.4%
ROA7.9%
ROIC (approx.)23.0%
Asset turnover0.70x

Leverage & solvency

Liabilities / assets59.4%
Debt / equity0.47x
Current ratio2.75x
Interest coverage5.44x

Cash quality & payout

Operating cash flow / net income1.96x
Accruals ratio-7.6%
Payout ratio0.0%
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$290.78M$266.04M$237.46M$247.06M$227.81M$211.37M$197.12M$190.57M
Cost of revenue$111.53M$100.16M$93.58M$100.27M$93.39M$74.61M$73.04M$80.28M
Gross profit$179.25M$165.89M$143.88M$146.79M$134.42M$136.76M$124.08M$110.29M
R&D expense$13.00M$14.75M$10.60M$12.26M$12.30M$16.54M$10.56M$16.65M
SG&A expense$94.86M$91.66M$73.66M$82.79M$76.66M$81.77M$76.53M$69.72M
Operating income$52.37M$40.46M$38.89M$34.77M$36.24M$13.89M$26.19M-$4.38M
Interest expense$7.59M$7.50M$7.55M$7.96M$8.28M$8.22M$8.11M$8.80M
Pretax income$49.04M$37.10M$40.22M$31.48M$33.80M$10.53M$19.99M-$13.76M
Income tax$13.89M$12.39M$10.73M$3.99M$7.18M$1.98M$4.31M-$3.49M
Net income$35.15M$24.71M$29.49M$27.49M$26.62M$8.55M$15.68M-$10.28M
EBITDA$71.92M$60.10M$59.81M$57.38M$58.87M$37.17M$49.09M$18.22M
EPS (basic)1.541.091.31—1.190.370.70—
EPS (diluted)1.511.051.28—1.130.360.69—
Weighted avg. shares (diluted)21.68M21.91M21.54M—21.09M20.31M20.05M—
Balance sheet
Cash & equivalents$420.76M$360.21M$311.18M$285.58M$262.61M$217.83M$149.80M$144.86M
Receivables$304.45M$274.47M$255.43M$281.08M$252.62M$225.65M$220.33M$221.73M
Inventory$136.41M$143.15M$143.47M$143.07M$146.47M$138.31M$137.41M$136.78M
Current assets$902.82M$825.43M$747.08M$753.12M$698.40M$602.63M$536.29M$528.46M
PP&E, net$81.55M$73.22M$67.11M$62.48M$63.56M$59.25M$58.18M$56.86M
Goodwill$62.48M$62.48M$62.48M$62.48M$62.48M$60.53M$60.66M$59.99M
Intangibles$433.11M$449.86M$467.16M$479.53M$499.82M$520.32M$538.50M$541.83M
Total assets$1.57B$1.49B$1.42B$1.44B$1.41B$1.34B$1.29B$1.28B
Current liabilities$328.72M$283.65M$239.51M$278.11M$270.56M$236.84M$201.81M$194.45M
Short-term debt$23.36M$21.33M$19.30M$17.27M$15.24M$13.22M$11.19M$9.17M
Long-term debt$274.31M$280.15M$286.00M$291.84M$297.68M$301.48M$305.29M$309.11M
Total debt$297.68M$301.48M$305.29M$309.11M$312.92M$314.70M$316.49M$318.28M
Total liabilities$930.55M$896.90M$859.67M$899.65M$902.34M$881.39M$848.96M$855.94M
Shareholders' equity$637.11M$597.21M$562.30M$540.72M$505.82M$436.76M$418.62M$403.68M
Net debt-$123.08M-$58.73M-$5.88M$23.52M$50.31M$96.87M$166.69M$173.42M
Shares outstanding———22.49M———21.11M
Cash flow statement
Operating cash flow$83.79M$56.67M$58.38M$30.37M$44.05M$75.81M$34.99M$15.86M
Capital expenditure$13.50M$3.05M$6.07M$1.24M$6.10M$4.01M$2.47M$2.39M
Free cash flow$70.28M$53.62M$52.30M$29.12M$37.95M$71.80M$32.52M$13.47M
Investing cash flow-$13.50M-$3.05M-$11.32M-$1.40M-$6.16M-$6.91M-$19.85M-$10.68M
Financing cash flow-$9.83M-$4.65M-$21.62M-$4.64M$6.34M-$1.75M-$9.91M-$4.91M
Depreciation & amortization$19.55M$19.64M$20.92M$22.61M$22.63M$23.28M$22.89M$22.60M
Stock-based compensation$11.63M$11.41M$10.19M$9.77M$9.69M$9.60M$8.87M$7.06M
Dividends paid$0$0$0$0$344,000$407,000$406,000$406,000
Share buybacks-$13.58M$813,000$19.75M$611,000$1.04M$551,000$10.00M$318,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.